Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Del Gaudio I, Sasset L, Di Lorenzo A, Wadsack C. Sphingolipid Signature of Human Feto-Placental Vasculature in Preeclampsia. Int J Mol Sci. 2020;21(3).

Vaidya P, Bera K, Gupta A, Wang X, Corredor G, Fu P, et al. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction. Lancet Digit Health. 2020;2(3):e116-e128.

Zanazzi G, Liechty BL, Pendrick D, Krasnozhen-Ratush O, Snuderl M, Allen JC, et al. Diffuse midline glioma with novel, potentially targetable, fusion. Cold Spring Harb Mol Case Stud. 2020;6(5).

Fischer K, Fenzl A, Liu D, Dyar KA, Kleinert M, Brielmeier M, et al. The scaffold protein p62 regulates adaptive thermogenesis through ATF2 nuclear target activation. Nat Commun. 2020;11(1):2306.

Turner SD, Inghirami G, Miranda RN, Kadin ME. Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Am J Pathol. 2020;190(1):2-10.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, et al. Publisher Correction: Building an international consortium for tracking coronavirus health status. Nat Med. 2020;26(8):1309.

Chadburn A, Chen Y-, Nayar R, Young A, Sumpter I, Lee C, et al. Limited Tissue Samples: Hematopoietic Lesions - Three Case Examples of Judicious Use of Limited Material. Acta Cytol. 2020;64(1-2):71-80.

Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020;80(12):1012-1023.

Basourakos SP, Kasabwala K, Silich R, Mosquera JM, Choi B. Neurofibroma originating from a urachal mass. Can J Urol. 2020;27(5):10407-10410.

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870-1881.